A second phase III trial of arhalofenate in combination with febuxostat in patients with chronic gout

Trial Profile

A second phase III trial of arhalofenate in combination with febuxostat in patients with chronic gout

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Arhalofenate (Primary) ; Febuxostat
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 09 Aug 2016 According to a CymaBay Therapeutics media release, the company has completed End-of-Phase 2 discussions with the FDA and reached agreement on all of the key elements of the planned Phase 3 program.
    • 22 Jan 2016 New trial record
    • 20 Jan 2016 According to a CymaBay Therapeutics media release, this is one of the 3 phase III trials that will support registration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top